- Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 -

- 协议授予安斯泰来独家全球权利（不包括中国大陆、香港、澳门和台湾地区）开发和商业化XNW27011 -

- XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study of patients with solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer -

- XNW27011在正在进行的针对实体瘤（包括胃癌、胃食管癌和胰腺癌）患者的1/2期研究中展现了令人鼓舞的单药疗效 -

- Evopoint to receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved -.

- Evopoint将获得1.3亿美元的首付款，并有资格获得高达7000万美元的近期付款，以及与开发、监管和商业化里程碑相关的额外里程碑付款，总额高达13.4亿美元，如果XNW27011获批，还将获得基于净销售额的特许权使用费。 -

TOKYO, Japan and SUZHOU, China, May 30, 2025

日本东京，中国苏州，2025年5月30日

, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2.

安斯泰来制药公司（TSE：4503，总裁兼首席执行官：冈村直树，“安斯泰来”）和亿方生物科技（亿方生物科技有限公司）今天宣布，双方已就一款新型临床阶段研究性抗体药物偶联物（ADC）XNW27011达成独家许可协议，该药物靶向CLDN18.2。

The agreement grants Astellas a worldwide (excluding China’s mainland, Hong Kong, Macao and Taiwan region) exclusive license to develop and commercialize XNW27011..

该协议授予安斯泰来在全球（不包括中国大陆、香港、澳门和台湾地区）独家开发和商业化XNW27011的许可。

XNW27011 is currently being evaluated in a Phase 1/2 study in China in patients with CLDN18.2-expressing solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer. It uses a proprietary topoisomerase I inhibitor payload and linker technology, an approach that has demonstrated clinical success in other approved cancer therapies..

XNW27011目前正在中国进行一项针对表达CLDN18.2的实体瘤患者（包括胃癌、胃食管癌和胰腺癌）的1/2期临床研究。它采用了专有的拓扑异构酶I抑制剂载荷和连接子技术，这种方法在其他已获批的癌症疗法中已显示出临床成功。

Astellas has significant expertise in developing therapies that target CLDN18.2, including VYLOY

安斯泰来在开发针对CLDN18.2的疗法方面拥有显著的专业知识，包括VYLOY。

TM

商标

, the first CLDN18.2-targeted therapy approved in the world. XNW27011 has the potential to address currently unmet patient need and will expand Astellas’ oncology pipeline which currently contains CLDN-targeting therapies utilizing different approaches, as well as ADC’s directed to other targets.

，这是全球首个获批的CLDN18.2靶向疗法。XNW27011有望满足当前未被满足的患者需求，并将扩展安斯泰来目前的肿瘤学管线，该管线包含采用不同方法的CLDN靶向疗法，以及其他靶点的ADC药物。

Under the terms of the agreement, Evopoint will receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved..

根据协议条款，益诺思将获得1.3亿美元的首付款，并有资格获得高达7000万美元的近期付款，以及与开发、监管和商业化里程碑相关的额外里程碑付款，总额高达13.4亿美元。此外，如果XNW27011获得批准，益诺思还将获得该产品净销售额的特许权使用费。

Adam Pearson, Chief Strategy Officer, Astellas

亚当·皮尔逊，安斯泰来首席战略官

“Astellas is dedicated to advancing innovative therapies for some of the most challenging-to-treat cancers, such as gastric and pancreatic cancer. XNW27011 is a promising new asset that complements Astellas’ pipeline and enhances our leading position in precision oncology. We look forward to harnessing our expertise in targeting CLDN18.2 and specialized knowledge in GI cancers to advance XNW27011 and deliver meaningful outcomes to patients.”.

“Astellas致力于推进一些最难治疗的癌症（如胃癌和胰腺癌）的创新疗法。XNW27011是一项很有前景的新资产，它补充了Astellas的研发管线，并巩固了我们在精准肿瘤学领域的领先地位。我们期待利用我们在靶向CLDN18.2方面的专业知识以及在胃肠道癌症方面的专长，推动XNW27011的发展，为患者带来有意义的成果。”

Arthur Qiang, Chairman, Evopoint

强亚瑟，Evopoint董事长

“XNW27011 is a novel investigational antibody-drug conjugate that has shown great promise in the clinic. Astellas has a proven history of developing and commercializing a strong franchise of innovative cancer therapies. We are pleased to enter into this new license agreement to further our collective goals of bringing new treatment options for patients in need worldwide.”.

“XNW27011 是一种新型的研究性抗体药物偶联物，在临床上展现了巨大的潜力。Astellas 在开发和商业化创新型癌症治疗方案方面有着可靠的历史。我们很高兴达成这项新的许可协议，以进一步实现我们为全球有需要的患者提供新治疗选择的共同目标。”

About Astellas

关于安斯泰来

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need.

安斯泰来是一家全球生命科学公司，致力于将创新科学转化为对患者的 VALUE。我们在肿瘤学、眼科、泌尿科、免疫学和妇女健康等疾病领域提供变革性疗法。通过我们的研发计划，我们正在为那些存在高度未满足医疗需求的疾病开拓新的医疗解决方案。

Learn more at .

了解更多，请访问。

www.astellas.com

www.astellas.com

.

。

About Evopoint Biosciences

关于Evopoint生物科学

Evopoint Biosciences is an innovative biopharmaceutical company with exceptional capabilities in R&D and commercialization. Since its inception, Evopoint has been committed to improving human health by discovering and developing cutting-edge pharmaceutical solutions that address significant unmet medical needs worldwide.

Evopoint Biosciences是一家创新型生物制药公司，具备卓越的研发和商业化能力。自成立以来，Evopoint一直致力于通过发现和开发满足全球重大未满足医疗需求的前沿药物解决方案来改善人类健康。

Leveraging diverse discovery platforms in targeted therapy, ADC, and targeted protein degradation (TPD), the company has built a robust pipeline focused on oncology, infectious diseases and metabolic diseases. Learn more at .

利用多种发现平台开展靶向治疗、抗体偶联药物（ADC）和靶向蛋白降解（TPD），公司已建立了一条专注于肿瘤学、传染病和代谢疾病的强大管线。欲了解更多信息，请访问 。

www.evopointbio.com

www.evopointbio.com

.

。

Astellas Cautionary Notes

安斯泰来警示说明

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties.

在本新闻稿中，关于当前计划、估计、策略和信念的陈述以及其他非历史事实的陈述是关于安斯泰来未来业绩的前瞻性陈述。这些陈述基于管理层当前的假设和信念，并结合其目前可获得的信息，涉及已知和未知的风险与不确定性。

A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

许多因素可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异。这些因素包括但不限于：(i) 与医药市场相关的总体经济状况、法律法规的变化，(ii) 汇率波动，(iii) 新产品发布的延迟，(iv) 安斯泰来无法有效营销现有和新产品，(v) 安斯泰来无法在竞争激烈的市场中继续有效研发客户认可的产品，以及 (vi) 第三方侵犯安斯泰来的知识产权。

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice..

本新闻稿中包含的关于药品（包括正在开发中的产品）的信息并非旨在构成广告或医疗建议。

Click below for a copy of the full press release

点击下方获取完整新闻稿的副本